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Abstract In a recent randomized, double-blind, placebo-
controlled trial, we established a robust efficacy (Cohen’s
d = 2.17) of osmotic release oral system-methylphenidate
(OROS-methylphenidate) delivered 72 mg daily for
5 weeks versus placebo on attention deficit hyperactivity
disorder (ADHD) symptoms, global severity and global
functioning in 30 adult male prison inmates with ADHD
and coexisting disorders. Outcomes continued to improve
during the subsequent 47-week open-label extension with
OROS-methylphenidate delivered at a flexible daily dosage
of up to 1.3 mg/kg body weight. In the present study, we
evaluated long-term effectiveness and maintenance of
improvement over the cumulated 52-week trial on cogni-
tion, motor activity, institutional behaviour and quality of
life. Post hoc, we explored the associations between
investigators’ and self-ratings of ADHD symptoms and
between ratings of symptoms and functioning, respectively.
Outcomes, calculated by repeated measures ANOVA,
improved from baseline until week 16, with maintenance or
further improvement until week 52. Both verbal and vis-
uospatial working memory, and abstract verbal reasoning
improved significantly over time, as well as several cog-
nition-related measures and motor activity. No substance
abuse was detected and a majority of participants took part
in psychosocial treatment programmes. The quality of life
domains of Learning, and Goals and values improved over
time; the latter domain was at open-label endpoint signif-
icantly related to improvements in attention. Investigators’
and self-ratings of ADHD symptoms, as well as global
symptom severity related most significantly to global
functioning at week 52. Finally, investigators’ and self-
ratings of ADHD symptoms associated significantly at
baseline with increasing convergence over time.
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Introduction
Attention deficit hyperactivity disorder (ADHD) is a
common, inherited disorder, which arises during childhood
and frequently persists into adulthood. ADHD is charac-
terized by developmentally inappropriate levels of inat-
tention, hyperactivity and impulsivity [1]. Behavioural
symptoms and cognitive deficits associated with ADHD
have been extensively explored, especially in children.
However, it is less known to what extent treatment ame-
liorates these associated cognitive deficits [2]. Tradition-
ally, symptoms of hyperactivity have been assumed to
decline by age and to change from gross motor overactivity
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as commonly observed in children, to a more subtle sense
of inner restlessness in adults with ADHD [3]. However,
increased levels of motor activity have recently been
observed in adults with ADHD by means of objective
measurements, contradicting the view of motor activity not
being of a concern in adults [4]. There has also been a shift
in the understanding of cognitive deficits associated with
ADHD, from earlier theories suggesting a core deficit in
response inhibition as part of a frontal lobe dysfunction, to
an explanation of multiple cognitive deficits [2]. This new
understanding is supported by the observed heterogeneity
of cognitive impairments seen in ADHD samples, and the
observation of executive function deficits, such as impair-
ments in working memory, organizing and planning—
although common, not being present in all individuals with
ADHD [5, 6]. Despite the evidence of a strong genetic
contribution to ADHD, results of candidate gene associa-
tions have yielded inconsistent results, suggested to be
reflective of the heterogeneity and complexity of ADHD.
Therefore, it has been proposed that the use of neuropsy-
chological endophenotypes might facilitate in the detection
of genetic effects [7]. Further, neuroimaging studies have
demonstrated structural differences and deficits in the
activation of several brain areas, and studies using neuro-
physiology have suggested a disturbed neuronal inhibition
within individuals with ADHD [2, 8–11]. The functional
impairments of ADHD related to core symptoms and
cognitive deficits, affect several aspects of daily function-
ing, such as education, work performances, social rela-
tionships and quality of life [1, 12, 13]. Also, almost 80 %
of adults with ADHD present with coexisting psychiatric
disorders [5, 14]. Among these, substance use disorder and
antisocial personality disorder are common, both increas-
ing the risk of subsequent delinquency. Several studies
estimate ADHD to be present among 25–45 % of adult
prison inmates, as compared to about 2–5 % of adults in
the general population [1, 15–17]. In prison inmates,
ADHD is most often combined with externalizing symp-
toms of conduct disorder (CD), usually childhood-onset
CD, but also adolescent-onset CD is reported. Recently, it
has become evident that CD is the dominating risk factor in
mediating later development of antisocial and delinquent
behaviour, not ADHD alone [18]. It is estimated that about
half of children with ADHD develop CD, and about half of
them with CD subsequently develop antisocial personality
disorder. In contrast to DSM-IV, the classification system
of ICD-10 defines a category of hyperkinetic disorder of
social behaviour (F90.1), thus differentiating between
ADHD and ADHD with CD [18].
Treatment with methylphenidate demonstrates short-
term efficacy in improving core symptoms of ADHD and is
therefore often considered the drug of first choice, both in
children and in adults [5, 19, 20]. Reports of long-term
effectiveness of stimulants in children show mixed results.
The MTA study conducted in children with ADHD
reported temporary long-term effects that dissipated over
time [21], as opposed to studies reporting long-term ben-
efits of treating youths with ADHD [22, 23]. Reports of
long-term effectiveness of stimulants in adults with ADHD
are even sparser. These long-term studies mostly comprise
open-label extensions of controlled short-term trials, but
also long-term controlled trials and observational studies of
clinical cases are reported. Taken together, the limited data
suggest maintenance of treatment response to stimulants
over 6 months—2 years, without developing tolerance of
treatment effects [24–29]. However, more data on long-
term effects in different study populations are warranted to
clarify and differentiate between long-term effects and
effects of long-term treatment.
In addition, participants of clinical pharmacological
trials typically demonstrate less functional impairments,
lower rates of lifetime coexisting psychiatric disorders, and
higher occupation and socioeconomic status than individ-
uals with ADHD seen in clinical practice. These notions
suggest that results from many clinical trials may have
limited external validity [30].
Moreover, the few studies that have evaluated methyl-
phenidate treatment in participants with ADHD and coex-
isting substance use disorder could not establish efficacy as
compared with placebo in improving ADHD symptoms
[31]. And despite the high prevalence of ADHD in prison
inmates, pharmacological treatment has not previously
been evaluated in this group. Further, most trials have
primarily evaluated effectiveness of pharmacotherapy on
ADHD core symptoms, global functioning and global
severity in the short term, with limited information
regarding effects on cognition, and long-term outcomes of
stimulant treatment in individuals with ADHD [2]. Most
evaluations so far have been conducted in children, with
reports of larger improvements on tasks without an exec-
utive component than on those with executive components
[32, 33]. According to these studies, the optimal dose
appears to vary across individuals, suggesting requirement
of lower doses for improvement in cognitive symptoms
than for behavioural ones. There has however not been any
clear evidence of methylphenidate fully correcting cogni-
tive deficits related to ADHD [34]. Studies evaluating
effects of stimulants on neuropsychological performances
in adult ADHD have shown mixed results [2, 35]. Briefly,
the most consistent finding is improvement in vigilance or
sustained attention [2, 35]. So far, only a few studies have
evaluated the association between symptomatic improve-
ments and improvements in daily functioning by ADHD
treatment. These studies have suggested a translation of
symptomatic improvements into functional improvements
[27, 36–38]. This translation might be understood in such a
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way that individuals that become more attentive, structured
and patient as a result of treatment, improve their ability to
interact with family members, friends and co-workers, thus
increasing their levels of social and daily functioning.
Further, based on the observation of a correlation between
investigators’ and self-ratings of ADHD symptoms in
adults [39], it could be suggested that self-ratings would be
reliable enough to replace investigators’ ratings. However,
this question need to be further explored. We recently
reported a randomized, double-blind, placebo-controlled
5-week trial, followed by 47-week open-label extension,
conducted in 30 adult male prison inmates with ADHD and
coexisting disorders [40]. When designing this trial, we
aimed at increasing the external validity of results by
allowing for participants with ADHD and coexisting dis-
orders, thus being representative for a prison population.
Further, as this was, to our best knowledge, the first con-
trolled trial of stimulants for ADHD, conducted within a
prison setting, we aimed at gathering a broader range of
information regarding treatment effects. Therefore, we
assessed outcomes of symptoms, functioning, cognition,
institutional behaviour, quality of life, adverse events and vital
signs, both in the short-term and in the long-term. OROS-
methylphenidate delivered 72 mg daily significantly
improved ADHD core symptoms, global severity and global
functioning versus placebo. All 30 participants entered the
subsequent 47-week open-label extension without compara-
tor. During this phase, OROS-methylphenidate delivered at a
flexible daily dosage of up to 1.3 mg/kg body weight further
improved outcomes within participants [40].
The present paper reports secondary outcomes of this
cumulated 52-week trial. We evaluated the long-term effec-
tiveness and maintenance of treatment effects from OROS-
methylphenidate on cognition, motor activity, institutional
behaviour and quality of life, from baseline until end of
treatment after 52 weeks. Post hoc, we explored the rela-
tionships between ratings of symptoms and daily functioning,
and between investigators’ and self-ratings of ADHD symp-
toms, respectively. We hypothesized that OROS-methylphe-
nidate would improve aspects of cognition, motor activity,
institutional behaviour and quality of life and that improve-
ments would maintain over the entire 52-week study period.
Finally, we hypothesized that ratings of symptoms and func-
tional outcomes, as well as investigators’ and self-ratings of
ADHD symptoms would be significantly associated.
Methods
Participants
Adult male prison inmates confirmed with ADHD took part
in the present study. All participants were hosted at
Norrta¨lje Prison, located outside Stockholm, Sweden. This
high-security prison hosts primarily long-term, adult male
inmates convicted of drug-related or violent crimes. The
initial screening survey and diagnostic assessments were
previously reported in detail [15]. All assessments were
performed by experienced board-certified psychiatrists and
clinical psychologists. Briefly, ADHD was confirmed by a
clinical interview assessing symptoms and impairments of
ADHD during both childhood and adulthood, in consistent
with DSM-IV criteria [41]. Diagnostic assessments also
included collection of information from parents, school
records, health services, and the prison and probation ser-
vice, regarding developmental history, current symptoms
and impairments. Coexisting disorders were evaluated by
the Structured Clinical Interview for DSM-IV Axis I Dis-
orders (SCID I) [42], the Hare Psychopathy Check List-
Revised (PCL-R) [43] and the SCID II Patient Question-
naire (SCID II PQ), a self-rated version of the Structured
Clinical Interview for DSM-IV Axis II Personality Disorders
[42]. Additional assessments included obtainment of medical
history, physical examination, routine laboratory tests,
supervised urine drug screening and neuropsychological tests
assessing IQ and executive functions. When appropriate,
assessments were extended for confirming autism-spectrum
disorder in consistence with DSM-IV criteria [41].
Participants randomized to the clinical trial had to be
established with ADHD in consistence with DSM-IV and
to agree not to behave violently during the trial. Coexisting
disorders, such as anxiety, depression and autism-spectrum
disorder, were allowed. Previous drug-elicited episodes of
psychosis or psychopathy as defined by Hare (total sum-
score C30) were not a cause for exclusion. Concurrent
medication not interfering with methylphenidate was
allowed for treating coexisting disorders, as long as doses
were kept stable for at least 4 weeks at baseline. Pharma-
cological treatment interfering with methylphenidate had to
be tapered off in advance to the baseline visit. Also, par-
ticipants had to be confirmed without substance abuse
during the preceding 3 months and should not fulfil the
diagnostic criteria for mental retardation or for any serious
medical illness. However, participants with hepatitis C
without liver insufficiency could take part in the trial. Full
details of the study design, inclusion and exclusion criteria
have been reported previously [40].
Study design
This study (ClinicalTrials.gov:NCT00482313) was a ran-
domized, double-blind, placebo-controlled parallel-group
5-week trial, followed by a 47-week open-label extension.
It was conducted between May 2007 and April 2010 in 30
adult male prison inmates. Participants were randomly
assigned to placebo or OROS-methylphenidate at a ratio of
Eur Arch Psychiatry Clin Neurosci (2012) 262:705–724 707
123
1:1. The study was approved by the Ethical Board of
Stockholm, Sweden (2006/1141-31/3), and by the Swedish
Medical Products Agency (EudraCT-nr 2006-002553-80),
respectively. All participants provided written informed
consent after they had received a thorough description of
the study. The trial was independently monitored by the
Karolinska Trial Alliance and inspected by the Swedish
Medical Products Agency to validate adherence to Good
Clinical Practice and the Declaration of Helsinki.
Study intervention
The study drug was titrated from 36 mg daily for 4 days to
54 mg daily for 3 days and then to 72 mg daily for the
remaining 4 weeks. All participants that completed the
5-week trial were eligible to enter the 47-week open-label
extension, starting the day after completion of the 5-week
phase. During the open-label extension, OROS-methylphe-
nidate was individually titrated from 36 mg daily to an opti-
mal dose, on the basis of response and tolerability, with a
maximum daily dose of 1.3 mg/kg body weight. In case of
intolerable adverse events, lower doses were administered,
followed by increased doses once participants recovered from
the adverse event. In addition to study medication, participants
were, as part of regular prison routines, provided educational
activities and accredited treatment programmes. However,
these psychosocial interventions did not specifically address
symptoms and associated impairments of ADHD.
Assessments
Assessments of self-reported Quality of Life Inventory
(QOLI) [44], as well as neuropsychological assessments
performed by certified psychologists, were conducted at
baseline (T1), at study week 16 (T2) and at endpoint study
week 52 (T3), with the exception of the WAIS-III subtest
Similarities [45], which was assessed at baseline (T1), and at
study week 52 (T3) only. Information regarding participation
in educational activities was recorded by the teachers, whereas
correctional officers recorded what treatment programmes
participants took part in, as well as critical incidents that
occurred for each participant throughout the study.
Outcome measures
The Digit Span and the Span Board
Changes in verbal working memory capacity were measured
by the Digit Span, a subtest of WAIS [45]. The corresponding
non-verbal task Span Board measured changes in visuospatial
working memory [46]. Results of both tests are expressed on
age-scaled scores, with a population mean of 10 (M = 10) and
a standard deviation of 3 (SD = 3). For further analyses of
different aspects of working memory performances, we
divided the results of both tests into forward and backwards
performances, respectively. Forward performances are asso-
ciated with maintenance of information in working memory.
On the other hand, backwards performances relate to both
maintenance and manipulation of information in working
memory, thus comprising a more demanding task. These
divided measures were reported as number of correctly indi-
cated series.
Similarities
The WAIS-III subtest Similarities [45] is a measure of
abstract verbal reasoning. Similarities is not expected to
show learning effects from repeated testing, especially not
with long test–retest interval, as in the present study. It was
used as a specificity measure for the assessments performed
during the study, thus only administered at baseline (T1)
and at study week 52 (T3).
The Conners’ Continuous Performance Test II
The Conners’ Continuous Performance Test II (Conners’
CPT II) [47] is a computerized visual continuous perfor-
mance test (CPT). During this 14-min lasting go/no go test,
letters are presented on a computer screen and the partic-
ipant is instructed to respond both accurately and fast by
pressing a button for each letter except the letter ‘‘X’’.
Measures are grouped into those reflecting functions such
as basic reaction time, variability and accuracy. Results of
the CPT are expressed as T-scores, corresponding to a
population norm with M = 50 and SD = 10. Shortly,
higher scores reflect poorer performances.
The QbTest
The QbTest combines a simultaneous delivered computerized
visual CPT with a high-precision infrared motion tracking
device (provided by Qbtech, Stockholm, Sweden;
www.qbtech.se/products/qbtest; QbTest technical manual,
Fredrik Ulberstad, Rev E, January 2012). Motions are cap-
tured and recorded by a reflective headband marker, with a
sampling rate of 50 times per second and a spatial resolution of
1/27 mm per infrared camera unit. The test duration is 20 min,
but to adjust for test adaptation, only data from the last 15 min
are analysed. Four different types of stimuli, varying in colour
(blue, red) and shape (square, circle) are presented on the
computer screen in a pseudorandom order. The participant is
instructed to react as fast and accurate as possible and press a
button when the currently presented stimulus matches with the
stimulus presented directly before, in both shape and colour.
Otherwise, the participant is instructed not to press the button,
corresponding to inhibiting the motor response. This 1-back
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working memory task used in the adult version of QbTest is
more challenging than the go/no go task provided by the
Conners’ CPT II and therefore suggested to be a more
appropriate task for adults. The QbTest measures are grouped
into those related to motor activity and cognition, as presented
in Table 4. Due to skewed distribution of data, raw scores are
transformed to age- and sex-scaled Q-scores, corresponding to
z-scores (norm population M = 0, SD = 1). QbTest dem-
onstrates good test–retest reliability (Ulberstad F, 2011, data
on file). Shortly, higher scores reflect poorer performances.
Institutional behaviour
Institutional behaviour was evaluated in several ways. As part
of regular prison routines, inmates are obliged to participate in
scheduled programmes during daytime (www.kriminalvar
den.se). These programmes comprise activities such as
vocational training, educational programmes and participa-
tion in evidence-based treatment programmes, aiming to
increase the chances in obtaining a job, as well as preventing
from continued substance abuse or return to crime after served
conviction. All treatment programmes are accredited by the
Swedish Prison and Probation Service. Each participant was
provided an individualized combination of programmes
decided by the participant’s assessed risks and needs. During
the present study, general offending programmes (OTO—
One To One, ETS—Enhanced Thinking Skills), programme
for violence prevention (aggression replacement training),
substance abuse programmes (dare to choose, PRISM—Pro-
gram for reducing individual substance misuse, twelve-step
programme), sexual offending programme (ROS—Relations
and companionship) and motivational programme (behav-
iour–talk–change) were provided. Educational programmes
adhering to the Swedish curriculum were provided by teachers
at the Learning center of Norrta¨lje Prison, with the purpose of
increasing basic skills such as reading, writing and mathe-
matics. Educational studies were preferably provided at the
primary school level, but it was also possible to study at high
school level or to continue university studies when appropri-
ate. Information regarding participation in treatment pro-
grammes and educational activities was collected by
correctional officers and teachers, respectively. Results were
reported by descriptive statistics.
Diversion of drugs is a matter of concern within many
prison settings. To control for substance abuse within
participants during the course of the study, supervised urine
drug screening was regularly performed by correctional
officers at the prison wing. Results of the drug screening
procedures were reported by descriptive statistics. Finally,
critical incidents that occurred during the course of the
study were recorded by prison officers and compared with
the number of incidents recorded during the corresponding
time period preceding the randomization of the participant.
The Quality of Life Inventory
Self-rated quality of life was assessed by a cross-cultural val-
idated Swedish version of the Quality of Life Inventory (QOLI)
[44]. This general, 32-item self-administered rating scale is
considered applicable to both non-psychiatric and psychiatric
populations. It measures satisfaction and importance of 16
different domains, reflecting areas of achievement, social
functioning, personal growth and surroundings [48, 49]. QOLI
is shown to be reliable, valid and sensitive to treatment-related
changes in several clinical populations [49, 50]. However, to
our best knowledge, quality of life measured by QOLI has not
previously been reported for ADHD populations.
The participant rates the degree of importance of each
life area to their overall happiness and satisfaction from
0 = not at all important to 2 = very important, and its
satisfaction with each domain from -3 = very dissatisfied
to ?3 = very satisfied, excluding 0. The importance and
satisfaction scores of each life area are then multiplied to
create 16 weighted satisfaction scores. A global index of
subjective quality of life, expressed as a total T-score,
comprises the sum of the weighted satisfaction scores in all
areas rated as important by the participant. However, since
life satisfaction may differ between specific domains, and
several domains were considered non-relevant or difficult
to influence within a restricted prison environment, we
decided to evaluate changes in the different domains
instead of using the single global index of life satisfaction.
The Conners’ Adult ADHD Rating Scale-Observer:
Screening Version
The investigator-rated Conners’ Adult ADHD Rating
Scale-Observer: Screening Version (CAARS: O-SV) [51]
comprises 18 items corresponding to the 18 DSM-IV
ADHD symptom criteria. This scale provides a total sum-
score, based on ratings of symptom frequencies from
0 = not at all, to 3 = very much/very frequently (range
0–54). The 18 items can be further divided into a 9-item
subscale of inattention (range 0–27), and a 9-item subscale
of hyperactivity/impulsivity (range 0–27), respectively.
The Adult ADHD Self-Report Scale
In the Adult ADHD Self-Report Scale (ASRS) [51], 18
items corresponding to the 18 ADHD symptom criteria of
DSM-IV are worded to be more reflective of the expression
of ADHD symptoms in adulthood. The participant rates the
frequency of each symptom from 0 = never to 4 = very
often, providing a total sum-score (range, 0–72). ASRS can
be further divided into a 9-item subscale of inattention
(range, 0–36) and a 9-item subscale of hyperactivity/
impulsivity (range, 0–36), respectively.
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The Clinical Global Impression Severity of Illness Scale
The investigator used the Clinical Global Impression-
Severity Scale (CGI-S) [52] to rate the participant’s global
symptom severity of ADHD on a 7-point scale, ranging
from 1 = not ill to 7 = extremely severe.
The Global Assessment of Functioning Scale
The investigator used the Global Assessment of Func-
tioning Scale (GAF) [53] to rate the participant’s global
functioning on a visual analogue scale, ranging 0–100. A
higher value reflects an increased level of functioning as
compared to a lower value.
Statistical analysis
The primary outcome measure of the clinical trial was the
change in investigator-rated ADHD symptoms from base-
line until end of week 5 in the double-blind phase, mea-
sured by the total sum-score of CAARS: O-SV. The sample
size was based on this primary outcome measure. Details of
the sample size calculation, as well as results of CAARS:
O-SV and secondary outcomes of global severity and
global functioning, were reported previously, together with
details of adverse events and vital signs during the cumu-
lated 52-week trial [40].
In this secondary analysis, we employed repeated mea-
sures analysis of variance (rmANOVA) for treatment
effects within participants on cognition-related measures
and measures of quality of life. Analyses were presented in
two ways, including (1) participants with complete data
from all assessments (per-protocol population) and (2) the
intent-to-treat population (ITT), defined as all randomized
participants providing baseline data. Last observation car-
ried forward (LOCF) was used for imputation of missing
data. Single missing values were handled conservatively by
substituting the missing value with the higher value from
the preceding or following visit. The effect size was pre-
sented by partial eta squared (gp
2) for efficacy measures and
interpreted using the guidelines as proposed by Cohen;
0.01 = small effect size, 0.06 = moderate effect size, and
0.14 = large effect size [54]. We expected the largest
changes in cognition and motor activity to occur between
baseline (T1) and study week 16 (T2). However, we also
evaluated changes between study week 16 (T2) and study
week 52 (T3), by performing tests of within-subjects con-
trasts, with simple contrasts using T3 as the reference level.
Significance levels and confidence intervals were adjusted
with Bonferroni corrections in the analyses of changes in
QOLI domains (0.05/16). Institutional behaviour was
reported by descriptive statistics. Alpha level was set at
P = 0.05 (two-sided significance).
Further, post hoc analyses were performed to explore the
relationships between investigator-rated (CAARS: O-SV)
and self-rated (ASRS) improvements in ADHD symptoms
and between symptomatic (CAARS: O-SV subscales,
ASRS subscales, CGI-S) and functional (GAF, QOLI
domains) ratings, based on completers. Due to the small
sample size, exploration of relationships between rating scales
was limited to the determination of bivariate correlation
coefficients. After checking for normality, Pearson’s product
moment correlation coefficients (r) were calculated for scores,
as well as for changes in scores of rating scales at baseline,
study week 16 and open-label endpoint at week 52.
Results
Participants
Baseline data demonstrated that coexisting disorders were
common; lifetime substance use disorder was reported by
all participants, all but one confirmed antisocial personality
disorder, a majority were established with mood and/or
anxiety disorders, and one-quarter confirmed concomitant
autism-spectrum disorder. At study entry, almost half of
participants received pharmacological treatment for mood
and/or anxiety disorders. Scores of rating scales revealed
that participants were substantially symptomatic and
impaired from ADHD at baseline (Table 1).
All 30 randomized male prison inmates, aged 21–61,
completed the initial 5-week randomized, double-blind,
placebo-controlled trial and entered the 47-week open-
label extension.
A total of 24 participants completed the cumulated
52-week trial, as seen from the study flow chart presented in
Fig. 1. However, 25 participants provided endpoint data, as
one participant was transferred from Norrta¨lje Prison in
advance due to improvement and therefore underwent end-
point assessments at study week 46. Full details of the initial
5-week trial and some of the secondary analyses from the
open-label extension were previously reported [40].
Briefly, during the initial double-blind phase, OROS-
methylphenidate significantly improved ADHD symptoms
(CAARS: O-SV, P\ 0.001; Cohen’s d = 2.17; ASRS,
P = 0.003), global symptom severity (CGI-S, P \0.0005)
and global functioning (GAF, P\ 0.0005). Numbers needed
to treat (NNT) was 1.1 (95 % CI, 1–2), and the placebo
response was observed to be non-significant. ADHD symp-
toms, global severity and global functioning continued to
improve during the open-label extension phase without com-
parator. At study endpoint at week 52, the mean dose of OROS-
methylphenidate was 105 (SD = 27.2) mg daily or 1.22
(SD = 0.28) mg/kg body weight daily, based on the ITT-
population. One serious adverse event of unknown cause
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occurred during the open-label extension, which justified study
withdrawal. Apart from this event, treatment was generally
well tolerated. Mucosal dryness was the only adverse event that
occurred more frequently in the OROS-methylphenidate group
than in the placebo group. Overall, the most frequently reported
adverse events, considered as associated with OROS-methyl-
phenidate, were abdominal discomfort, headache, mucosal
dryness, depressed mood, loss of appetite, anxiety, diarrhoea,
sweating, interrupted sleep and fatigue. The severity of adverse
events was usually rated as mild to moderate and did not lead to
discontinuation. There were no significant changes in blood
pressure, heart rate or body weight during the initial placebo-
controlled phase in either group. When considering the
cumulated 52-week trial, the group that received OROS-
methylphenidate from baseline, significantly increased both
the systolic (21.5 mmHg; 95 % CI 8.9–34.0) and the diastolic
(11.0 mmHg; 95 % CI 4.9–17.1) blood pressure, but there
were no significant changes in the heart rate or body weight. On
the other hand, in the group that received placebo during the
initial phase, the heart rate increased significantly (13.2 beats
per minute; 95 % CI, 7.0–19.4) over the cumulated 52-week
period, whereas body weight, systolic and diastolic blood
pressure remained almost unchanged.
Outcome measures
The Digit Span and the Span Board
A total of 25 participants completed all assessments. Both
verbal working memory measured by the Digit Span and
visuospatial working memory measured by the Span Board
Table 1 Baseline demographics, clinical characteristics and baseline
scores for randomized participants
Randomized
participants (n = 30)
Age (years)
Mean, SD 34.4 (10.67)
Range 21–61
Gender, male, n (%) 30 (100)
Educational level, 9 year compulsory
school, or less, n (%)
25 (83)
Educational support during childhood,
n (%)
24 (80)
Full scale IQ, (N = 22)
Mean, SD 95.18 (9.99)
Range 78–113
Adult ADHD subtypea, n (%)
Combined type 28 (93)
Predominantly inattentive 2 (7)
Autism-spectrum disordera,b, n (%) 7 (23)
Mood- and/or anxiety disordera, lifetime,
n (%)
22 (73)
Conduct disordera 30 (100)
Personality disordersa,c, (N = 23)
Antisocial, n (%) 22 (96)
Borderline, n (%) 17 (74)
Paranoid, n (%) 17 (74)
Narcissistic, n (%) 15 (65)
Obsessive-compulsive, n (%) 12 (52)
Passive-aggressive, n (%) 11 (48)
Avoidant, n (%) 11(48)
Depressive, n (%) 8 (35)
Dependent, n (%) 7 (30)
Schizotypal, n (%) 5 (22)
Schizoid, n (%) 2 (9)
Histrionic, n (%) 0 (0)
Substance use disordera, lifetime, n (%) 30 (100)






Anabolic steroids 1 (7)
Other 1 (7)
Psychopathyd 3 (10)
Treatment for psychiatric disorders at
baseline visit, n (%)
13 (43)
CAARS: O-SVe, baseline sum-score,
mean, 95 % CI
40.0 (38.1–41.8)
ASRSf, baseline sum-score, mean,
95 % CI
55.3 (52.0–58.6)
GAFg, baseline total score; mean, 95 % CI 35.2 (33.3–37.1)
Table 1 continued
Randomized
participants (n = 30)
CGI-Severityh, baseline score, mean,
95 % CI
5.9 (5.7–6.1)
Marked, n (%) 6 (20)
Severe, n (%) 21 (70)
Extremely severe, n (%) 3 (10)
a Diagnosis in accordance to DSM-IV
b Autism-spectrum disorders includes Asperger syndrome and per-
vasive developmental disorders, not otherwise specified (PDD-NOS)
c Frequencies of personality disorders were estimated by increasing
the cut-off level for each personality disorder by one score on the
SCID II Personality Questionnaire to equal the cut-off score of the
SCID II Interview
d Psychopathy was defined as a total sum-score of C30 by the Psy-
chopathy Check List-Revised (PCL-R)
e Conners’ Adult ADHD Rating Scale-Observer: Screening Version
f Adult ADHD Self-Report Scale
g Global Assessment of Functioning Scale
h Clinical Global Impression-Severity Scale
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improved significantly with large effect sizes within partici-
pants over time (Table 2; Fig. 2). Further, when analysing
components of working memory, neither Digit Span forward
nor Span Board forward improved significantly over time. In
contrast, both backwards tasks considered to be more working
memory demanding than the forwards tasks, improved across
time. Digit Span backwards improved significantly, whereas
Span Board backwards also improved but not significantly in
completers (P = 0.06). However, when the ITT-population
was analysed, Span Board backwards also improved signifi-
cantly (Table 2; Fig. 2). Post hoc analyses demonstrated that
working memory improved mainly between baseline and
week 16 (T2), without any further significant improvements
observed between week 16 (T2) and endpoint at week 52 (T3),
as presented in Table 2.
Similarities
The ability of verbal abstract reasoning, as measured by
Similarities, improved significantly within participants
with large effect sizes [54], between baseline (T1) and
open-label endpoint at week 52 (T3), in both completers
(n = 25) (F = 9.97, P = 0.004, gp
2 = 0.29) and the ITT-
population (F = 9.39, P = 0.005, gp
2 = 0.25).
The Conners’ Continuous Performance Test II
A total of 21 participants completed all three assessments
of Conners’ CPT II. As baseline data were missing for 3
participants due to technical error, the ITT-analyses using
LOCF included 27 participants. The reaction time was normal
within participants (M = 48.50, SD = 20.97) at baseline as
compared to the norm, and no statistical changes were
observed across the study period (Table 3; Fig. 3). Four out of
7 variability-dependent measures improved significantly over
time, as presented in Table 3. Notably, as we observed
extreme values (T-score [ 200) for 5 out of 21 participants in
Perseverations at baseline, they were considered as outliers.
To avoid confounding effects, statistics were performed both
with and without their values. However, Perseverations
Fig. 1 Study flow chart of participants in the cumulative 52-week trial
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improved significantly also when excluding values of the
outliers (F = 12.06, P = 0.002, gp
2 = 0.43). A total of 3 out
of 4 accuracy-dependent measures improved significantly
over time (Table 3). In summary, OROS-methylphenidate
improved 7 out of 12 Conners’ CPT II measures significantly,
with large effect sizes as measured by gp
2 [54]. The largest
improvements were observed between baseline (T1) and
study week 16 (T2), but some measures continued to improve
significantly also between study week 16 (T2) and endpoint at
study week 52 (T3), as depicted in Table 3.
The QbTest
A total of 24 participants provided complete data on
assessments of motor activity, and 23 participants (one
missing data due to technical error) provided complete data
on assessments of cognition by QbTest. Data are presented
as raw scores in Table 4, and as age- and sex-scaled
Q-scores in Fig. 4. Table 4 and Fig. 4 depict that all 5
measures related to motor activity improved
significantly over time, as did all 7 cognition-related
measures. Effect sizes expressed as gp
2 were large for most
measures [54], and the results of the per-protocol popula-
tion and the ITT-population were almost the same, as
evident from Table 4.
No further improvements were observed within partici-
pants between week 16 (T2) and week 52 (T3) in any
measure related to motor activity. However, 4 out of 7
cognition-related measures improved further and signifi-
cantly between study week 16 (T2) and open-label end-
point at week 52 (T3), as depicted in Table 4 and Fig. 4.
Institutional behaviour
A total of 24 participants out of 30 (80 %) took part in at
least one accredited treatment programme. About two-
thirds of them participated in two or three different pro-
grammes. The most frequently used programmes during
this study were general offending programmes, provided
individually and as a group intervention, as well as a
Table 2 Statistics from repeated measures ANOVAs for completers in both working memory tests, Digit Span and Span Board
n = 25 (n = 30 ITT/LOCF) F (F ITT) P (P ITT) gp
2 (gp





Digit Span Scaled Scores 6.33 (7.00) 0.004 (0.002) 0.21 (0.19) 0.007 0.198
Digits forward 1.91 (2.71) 0.167 (0.086) 0.07 (0.09) 0.318 0.424
Digits backwards 4.45 (4.73) 0.017 (0.013) 0.16 (0.14) 0.005 0.518
Span Board Scaled Scores 5.16 (5.72) 0.009 (0.005) 0.18 (0.17) 0.004 0.162
Span forward 0.39 (0.64) 0.680 (0.529) 0.02 (0.02) 0.584 0.461
Span backwards 3.03 (3.24) 0.057 (0.046) 0.11 (0.10) 0.021 0.942
Statistics for the intent-to-treat (ITT) population using last observation carried forward (LOCF) are presented within parentheses
Bold values indicate statistically significant P value
Italic values indicate the results of ITT-population
Bold italic values indicate statistically significant P values of the ITT-population
Fig. 2 Both verbal working
memory (Digit Span, panel to
the left) and visuospatial
working memory (Span Board,
panel to the right) improved
over time. The largest
improvements were observed
from baseline until study week
16. Data from completers
(n = 25) are presented in the
figure. Note: Asterisk indicates
the effect on repeated measure
P \ 0.05
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violence preventing programme conducted in a group set-
ting. A motivational programme and programmes pre-
venting continued substance abuse were also common. All
sexual offenders took part in a programme addressing
relations and companionship. Also, a vast majority, 26
participants out of 30 (87 %) took part in educational
programmes, mainly at the primary school level. Further,
no side abuse (0 %) was detected during the study, as
confirmed by supervised urine drug screening. Finally, we
also explored the number of reported critical incidents
during the 52 weeks preceding the trial. The number of
reports was clearly reduced during the trial compared with
the year before. However, most participants had spent the
year before entering the trial in other prisons, and because
we suspected there might be a methodological problem
with different reporting practices, we did not pursue these
analyses further with statistical tests.
Quality of Life Inventory (QOLI)
A total of 25 participants provided complete data on the
self-rated QOLI, assessed at baseline (T1), week 16 (T2)
and open-label endpoint at week 52 (T3). As presented in
Table 5, quality of life improved significantly over time
with a large effect size [54] in the specific domain of Goals
and values, both in completers (n = 25) (F = 12.78,
P \ 0.001, gp
2 = 0.53) and in the ITT-population (n = 30)
(F = 10.41, P \ 0.001, gp
2 = 0.43). Quality of life also
improved substantially in the Learning domain of both
completers (n = 25) (F = 15.53, P \ 0.001, gp
2 = 0.58)
Table 3 Statistics from repeated measures ANOVA of the Conners’ Continuous Performance Test II of completers, n = 21
n = 21 (n = 27 ITT/LOCF) F (F ITT) P (P ITT) gp
2 (gp





Hit reaction time 0.05 (0.04) 0.951 (0.924) 0.00 (0.00) 0.806 0.742
Variability-dependent measures
Hit reaction time standard error 16.38 (8.47) <0.001 (0.003) 0.45 (0.25) <0.001 0.014
Variability 22.82 (12.27) <0.001 (<0.001) 0.53 (0.32) <0.001 0.004
Hit reaction time block change 7.99 (5.17) 0.001 (0.013) 0.29 (0.17) 0.004 0.914
Hit standard error block change 0.45 (0.00) 0.640 (0.996) 0.02 (0.00) 0.388 0.948
Perseverations 9.35 (7.50) 0.006 (0.011) 0.32 (0.22) 0.005 0.048
Hit reaction time inter-stimulus intervals change 0.43 (0.36) 0.651 (0.695) 0.02 (0.01) 0.529 0.386
Hit standard error inter-stimulus intervals change 0.50 (0.064) 0.539 (0.854) 0.02 (0.00) 0.450 0.518
Accuracy-dependent measures
Omission errors 18.15 (9.46) <0.001 (0.002) 0.48 (0.27) <0.001 0.032
Commission errors 31.57 (18.66) <0.001 (<0.001) 0.61 (0.42) <0.001 0.071
Detectability 14.32 (9.96) <0.001 (<0.001) 0.42 (0.28) <0.001 0.255
Response style 1.40 (1.03) 0.257 (0.341) 0.07 (0.04) 0.234 0.675
Statistics from the intent-to-treat (ITT) population using last observation carried forward (LOCF) are presented within parentheses, n = 27;
baseline data were missing for three participants due to technical error
Bold values indicate statistically significant P value
Italic values indicate the results of ITT-population
Bold italic values indicate statistically significant P values of the ITT-population
Fig. 3 Seven out of twelve measures in the Conners’ Continuous
Performance Test II improved. Five participants with extreme values
at baseline (T-score [200) were excluded in the figure. Data from
completers (n = 21) are presented in the figure; baseline data were
missing for three participants due to technical error
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and the ITT-population (n = 30) (F = 16.23, P \ 0.001,
gp
2 = 0.54). As seen from Table 5, quality of life mainly
improved between baseline and study week 16, with
maintained improvements between study week 16 and
week 52.
Associations between symptomatic and functional
improvements
Pearson’s product moment correlation coefficients (r) for
symptom and functional rating scales are depicted in
Table 6. ADHD symptoms measured by both the inatten-
tion and the hyperactivity/impulsivity subscales of the
investigator-rated CAARS: O-SV, as well as the self-rated
ASRS, correlated negatively with global functioning
measured by GAF. The associations were evident from
study week 16 onwards, being the strongest at open-label
endpoint after 52 weeks of treatment, with correlation
coefficients (r) ranging from -0.483 to -0.736, as pre-
sented in Table 6. Further, both inattention subscales of
CAARS: O-SV and ASRS associated stronger with GAF
than the hyperactivity/impulsivity subscales. On the other
hand, global symptom severity measured by CGI-S was
negatively associated with GAF already from baseline
(r = -0.486, P = 0.006), with increased convergence
over time, to be most consistent by endpoint at week 52
(r = -0.885, P \ 0.001). Finally, QOLI correlated weaker
with symptomatic improvements than did GAF. The only
significant association of QOLI and symptomatic
improvement was the Goals and values domain, which
correlated negatively with the inattention subscales of both
CAARS: O-SV and ASRS. However, the associations were
significant only by the open-label endpoint at week 52
(CAARS: O-SV-Inattention, r = -0.414, P = 0.040;
ASRS-Inattention, r = -0.551, P = 0.004).
Associations between investigators’ and self-ratings
of ADHD symptoms
Investigator-rated ADHD symptoms by the total sum-score
of CAARS: O-SV correlated strongly with self-reported
ADHD symptoms by the total sum-score of ASRS, at all
assessments (T1, T2 and T3). The Pearson’s product
moment correlation coefficients (r) increased over time,
from baseline (T1) until open-label endpoint at week 52
(T3), ranging from 0.473 to 0.730 (all Ps \ 0.01) as shown
in Table 7.
Discussion
Recently, we reported primary findings from the first
controlled trial that evaluated treatment with OROS-
methylphenidate in prison inmates with ADHD and coex-
isting disorders [40]. This trial was carried out in 30 adult
males who served conviction mainly due to violent or drug-
related offences, and therefore were hosted at a high-
security prison. An initial 5-week randomized, double-
blind, placebo-controlled phase with OROS-methylpheni-
date delivered 72 mg daily was followed by an 47-week
open-label extension with OROS-methylphenidate deliv-
ered at a flexible daily dosage of up to 1.3 mg/kg
body weight in all participants. During the initial phase,
OROS-methylphenidate outperformed placebo robustly
(P \ 0.00 l, Cohen’s d = 2.17) in improvements in ADHD
symptoms, global severity and global functioning. These
outcomes continued to improve significantly within par-
ticipants during the open-label extension.
In the present study, we evaluated the long-term effec-
tiveness and maintenance of improvements from OROS-
methylphenidate over the cumulated 52 weeks of treat-
ment. Both verbal and visuospatial working memory, and
abstract verbal reasoning improved significantly within
participants, as well as cognition-related measures by
CPTs, motor activity and a few domains of self-reported
quality of life. Improvements mainly occurred between
baseline and study week 16, with maintenance or further
improvements in outcomes until open-label endpoint at
week 52. A vast majority of participants took part in
accredited treatment programmes as well as educational
activities, and no substance misuse was detected during the
course of the study. The post hoc correlation analyses
Fig. 4 Motor activity and cognition-related measures improved
significantly over time as measured by QbTest. Data from completers,
n = 23 (one missing data due to technical error) and n = 24,
respectively, are presented as age- and sex-scaled scores with a
population mean of 0 (M = 0) and a standard deviation of 1 (SD = 1)
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suggested that improvements in ADHD symptoms and
global symptom severity were all strongly associated with
functional improvement measured by GAF. Quality of life
measured by QOLI was on the other hand lesser associated
with symptomatic improvement than GAF. However, the
QOLI domain of Goals and values was related to
improvements in attention, but only significantly at open-
label endpoint. Finally, investigators’ and self-ratings of
ADHD symptoms were significantly associated from
baseline onwards, being most convergent by open-label
endpoint at week 52.
Previous studies have shown deficits in temporal, pari-
etal and frontal lobe function in both children and adults
with ADHD [2, 55]. Go/no go tasks used in CPTs have
demonstrated significant differences in commission errors,
variability of reaction time, omission errors and perceptual
sensitivity between individuals with ADHD and controls.
These deficits were associated with fMRI findings of
hypoactivation in specific brain regions in those with
ADHD, alongside hyperactivation in other areas, suggest-
ing the hyperactive regions to compensate for executive
dysfunction [10]. Recent fMRI studies have also discov-
ered an intrinsic organizational system of brain activity,
with a proposed functional connectivity between brain
regions in several temporally anti-correlated networks [9].
Temporal anticorrelation means that the so-called default
mode network is active during the resting state, as opposed
to the ‘task mode network’, which is active during task
performance. Consequently, both networks are not sup-
posed to be active at the same time.
One of the most consistent findings among individuals
with ADHD is increased reaction time variability as mea-
sured by CPTs. This reaction time variability is proposed to
reflect infrequent lapses of attention, related to insufficient
suppression of the default mode network [9]. That means
the default mode network seems to be active and interfer-
ing with the task mode network during task performance.
This is in line with a recent study, suggesting that indi-
viduals with ADHD have a relative weakness in sup-
pressing activity in the default mode network during
performance of a working memory task [56]. Our findings
of methylphenidate improving sustained attention and
reaction time variability, while also improving ADHD
symptoms, lend support to these previous findings. Our
observations are also consistent with a recent proposal of
stimulants facilitating the deactivation of the default mode
network, with corresponding decreases in lapses of atten-
tion, thus ameliorating symptoms of inattention [2].
In the present study, both verbal and visuospatial
working memory improved over time. This is in consis-
tence with a study by Fallu that reported improvements in
working memory functions within adults with ADHD that
participated in an open-label trial evaluating OROS-
methylphenidate [37].
Further, in the present study, objective quantification of
motor activity by QbTest showed a considerable motor
hyperactivity within participants. At baseline, they differed
by as much as 2–3 standard deviations as compared to the
norm group. The presence of objectively measured motor
hyperactivity in adults with ADHD is consistent with a
previous report by Lis et al. [4]. Both these observations
challenge the commonly held view of motor hyperactivity
not being of a concern in adults. The reason for the sub-
stantially increased motor activity observed in the present
study is not obvious. It might be that prison inmates with
ADHD represent a specific, homogeneous group of ADHD,
with substantially persistent and pervasive symptoms and
impairments across modalities. This suggestion is, at least
in part, supported by our previous report of prison inmates
being more symptomatic and dysfunctional as compared to
a group of adults with ADHD from a psychiatric outpatient
clinic [15]. However, more research is warranted to clarify
this issue. Moreover, OROS-methylphenidate significantly
decreased motor activity over time, although not to the
Table 7 Pearson’s product moment correlation coefficients (r) between investigator-ratings of ADHD symptoms by CAARS: O-SV and self-





ASRS, change in sum-score
from baseline to week 16
ASRS, sum-
score week 16
ASRS, change in sum-score
from baseline to week 52
ASRS, sum-score
week 52










Week 52, n = 25 0.730 (\0.001)**
P values are reported within parentheses
** P \ 0.01
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extent that motor activity was normalized as compared to
the norm. These findings are in line with a placebo-con-
trolled study conducted in children with ADHD that
observed atomoxetine to significantly decrease motor
hyperactivity as compared to placebo [57]. Our findings are
also in consistence with a study by Vogt and Williams [58].
They reported a robust treatment response on motor
activity measured by QbTest, in a group of children and
adolescents with hyperkinetic disorder who were admin-
istered a single dose of methylphenidate.
The Swedish Prison and Probation Service is part of the
judicial system. Their primary aims are both to reduce recid-
ivism in offences and to increase safety in society. In order to
reduce recidivism, they provide various accredited treatment
programmes, mainly addressing offending in general, vio-
lence and addiction. To increase the chances for inmates of
obtaining a job after conditional release, they are provided
work, vocational training and educational programmes. The
educational programmes aim at increasing basic skills such as
reading, writing and mathematics, preferably at the primary
school level. The participants of the present study were at
baseline substantially symptomatic from ADHD and coexis-
ting disorders, including lifetime substance use disorder. They
were also psychosocially dysfunctional and presented a very
low educational level. A vast majority (83 %) had fulfilled
9 years of compulsory school or less, and 80 % had received
educational support during childhood. Encouraging, as many
as 87 % of participants took part in educational programmes,
and 80 % took part in at least one accredited treatment pro-
gramme. Long-term follow-ups will be performed to explore
if taking part in the present study will be followed by reduced
recidivism in criminality and substance abuse among
participants.
Once imprisoned, individuals with untreated ADHD con-
stitute a challenge by their aggressive behaviour [17, 59, 60].
Correctional officers find these inmates difficult to manage,
both at the prison wings and in treatment programmes.
Aggressive behavioural disturbances will lead to reports on
critical incidents, often followed by formal sanctions, mean-
ing that inmates with ADHD will be less likely considered for
early release. In a previous study [59], inmates with ADHD
were accounted for eight times more reports on critical inci-
dents than inmates without ADHD. When controlled for
antisocial personality disorder, inmates with ADHD still
accounted for six times more reports than other inmates. The
increased risk for aggressive behaviour was found to be
related to factors such as persistence of ADHD symptoms,
impulsivity, mood instability, low frustration tolerance and a
disorganized/chaotic personality style. Therefore, effective
treatment combinations are warranted for prison inmates with
ADHD in order to reduce symptoms, improve control of
behaviour and affect regulation, as well as to improve pro-
social skills [60].
Considering the challenges and costs from handling
aggressive inmates, it is also of importance to evaluate
whether treatment with stimulants influences aggressive
institutional behaviour. In the present study, we observed
that critical incidents decreased during the study compared
with the year before. However, because of methodological
considerations, we did not employ inferential statistics.
Therefore, this issue still needs to be explored in future
studies. However, the vast majority of participants took
part in treatment programmes and educational activities.
For many of them, this was the first time they succeeded to
attend programmes. Our results are indeed promising and
suggest that stimulant treatment could be a useful part of a
more comprehensive intervention approach. To success-
fully benefit from psychological treatment, we consider it
essential to be able to concentrate, remain seated, and
process and remember the information presented at the
session. Pharmacological treatment could therefore facili-
tate for inmates to take part in psychological interventions
addressing ADHD and prosocial competence, such as
R&R2 for ADHD Youths and Adults [61].
Individuals with ADHD often self-report impairments in
quality of life [62]. Therefore, it is important to evaluate
the potential for stimulants to improve aspects of quality of
life. In the present study, we used QOLI, a general self-
reported questionnaire considered to apply to both non-
psychiatric and psychiatric populations. Most previous
studies that assessed QOLI, used a weighted, global index
of subjective life satisfaction, derived from the 16 specific
domains of QOLI. However, we decided to evaluate
changes in the specific domains instead of using the single
global index, since life satisfaction may differ between
specific domains, and several domains were considered
non-relevant for prison inmates and difficult to change
within the restricted prison environment. We observed
significant improvements in the domains of Goals and
values, and Learning, respectively. Also, domains of
health, self-regard, work, and relationships with relatives
improved over time, although not significantly. Impor-
tantly, participation in the educational programmes seems
to have improved self-reported quality of life, since the
domain of Learning was the one to improve the most. Also,
the domain of Goals and values in life improved substan-
tially over time, and at open-label endpoint, it was signif-
icantly associated with improvements in attention
subscales. How can we interpret these findings? We sug-
gest that symptomatic and functional improvements,
together with new experiences of succeeding at school and
in treatment programmes, as well as being able to control
behaviour instead of being reported for critical incidents,
contributed to increased self-respect and an improved sense
of internal locus of control. If a life situation becomes
possible to change, this could raise hope for the future.
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Goals in life that previously seemed impossible to reach
might become meaningful to consider. Also, the observed
improvements in cognition, such as working memory and
abstract verbal reasoning, might have facilitated in this
change of view.
Improvements in self-reported quality of life as
observed in this study are consistent with previous reports
of improved quality of life by treatment, although previous
studies used other quality of life questionnaires [62].
As most previous trials have demonstrated the effective-
ness of stimulants on ADHD symptoms, it was not fully
understood if symptomatic improvements translated into
functional improvements. However, the relationships
between symptomatic and functional improvements were
recently addressed in a few studies, suggesting a relationship
[27, 36–38]. Our post hoc analysis implied a strong associa-
tion between improvements in ADHD symptoms, rated by
both investigators and participants and functional improve-
ments by the investigator-rated GAF, which is in favour of the
previous suggested relationships between symptoms and
functions. However, quality of life domains of QOLI were
weaker associated with symptomatic improvement than GAF.
In fact, Goals and values was the only domain that signifi-
cantly related to symptomatic improvement, and only at the
open-label endpoint. This weaker association between quality
of life and symptomatic improvements might be related to the
use of QOLI, a general questionnaire rather than ADHD
specific. It might also be that QOLI was insufficiently sensi-
tive to detect changes within participants with ADHD spe-
cifically. As suggested previously, other explanations could be
that QOLI comprises domains, either non-relevant and/or
difficult to influence within a prison setting.
The post hoc analysis suggested a strong association
between investigators’ and participant ratings of ADHD
symptoms, which is in line with a previous report by Adler
et al. [39], who examined the psychometric properties of the
CAARS scale used in two studies of adult ADHD patients that
were randomized to 10-week treatment with atomoxetine or
placebo. The authors found that investigators’ and participant
ratings of ADHD symptoms (CAARS scales) were highly
variable at baseline, but the interrater reliability increased
substantially by the endpoint of treatment. This was suggested
to be reflective of the decreased frequency of ADHD symp-
toms from effective treatment, thereby reducing the variability
in symptom reports. It was also suggested that previously
untreated participants increased the ability over time to assess
and report their ADHD symptoms in a manner similar to the
investigators. Notably, in the present study, the variability also
seemed to be substantially reduced in cognition-related
measures, paralleling the reduced variability in symptom
reports (Tables 3, 4; Fig. 3).
Some limitations of the present study need to be consid-
ered when interpreting the results. The 47-week open-label
extension lacked a comparator, as only the initial 5-week
period was placebo-controlled. As a consequence, you
would expect larger effects from uncontrolled conditions,
not adjusting for non-specific effects as compared to a pla-
cebo-controlled trial. On the other hand, results of the neu-
ropsychological tests were all compared to norm group data,
which could be viewed as an indirect comparator. Further,
the study sample was small, thus limiting the range of sta-
tistical analyses being performed. Also, the study population
comprised prison inmates with ADHD and coexisting dis-
orders, including personality disorders, lifetime substance
use disorder, autism-spectrum disorder, antisocial behaviour,
anxiety and affective disorders. Results may therefore not be
generalizable to other adults with ADHD but without the
same spectrum of coexisting disorders. As this trial is the
first of its kind, conducted within a prison environment, we
are not able to compare our results with other similar studies.
However, when we compare the results of the present study
with results from previous studies conducted in adults with
ADHD, preferably from the general psychiatry, the effect
size of the present study (d = 2.17) by far exceeds the effect
sizes reported by previous studies. Most of these studies did,
however, exclude participants with substantial coexisting
disorders, thus not reflecting ADHD in the general popula-
tion. Therefore, based on our findings, we suggest that adults
with ADHD and coexisting disorders might improve more
from treatment than adults without coexisting disorders. As
the trial was conducted within a prison, treatment was
strictly controlled, as was compliance, thereby probably
contributing to the large effect sizes as seen in this study.
These results could therefore be difficult to translate into
regular clinical practice without the same controlled condi-
tions, thus likely resulting in a lower compliance to treat-
ment. Moreover, there were only single baseline assessments
of neuropsychological tests, which imply a risk for effects of
repeated testing. However, the effect sizes indicated very
large improvements by test norm standards that most likely
could not fully be explained by effects of repeated testing
alone. Also, effects were observed on tests in which effects
of repeated testing were not expected, such as abstract verbal
reasoning (Similarities), and verbal and non-verbal working
memory (Digit Span and Span Board, respectively). Another
limitation was that we used Similarities as a measure of
specificity. At forehand, we did not expect changes in
Similarities by OROS-methylphenidate treatment. However,
the ability of abstract verbal reasoning as measured by
Similarities, improved significantly over time, thus limiting
the usefulness of Similarities as a specificity measure. On the
other hand, it was encouraging that abstract verbal reasoning
actually improved, eventhough it was unexpected.
On the other hand, this study also has strengths. This
was the first study to evaluate OROS-methylphenidate as
treatment for prison inmates with ADHD and coexisting
Eur Arch Psychiatry Clin Neurosci (2012) 262:705–724 721
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disorders, and it is so far one of few long-term studies in
adults with ADHD that observed a robust treatment
response, both in the short term and in the long term.
Inclusion criteria were broader, allowing for the presence
of coexisting disorders, thus increasing generalizability of
results. The flexible dosing during the open-label exten-
sion aimed at reflecting regular clinical practice. Since
ADHD is a complex and heterogeneous disorder, we
aimed at exploring outcomes from a broader perspective,
incorporating several aspects of improvement, such as
symptoms, global functioning, cognition, motor activity,
institutional behaviour and quality of life. We also con-
ducted post hoc analyses that evaluated the translation of
symptomatic improvements into functional improve-
ments, and the associations between investigators’ and
self-ratings of ADHD symptoms. Based on our findings of
improved cognition in participants, we suggest a broad-
ening of outcome measures in future clinical trials to also
include objective measurements such as CPTs, with
tracking of motor activity. Moreover, the high correla-
tions between investigators’ and self-reported ADHD
symptoms, as well as between symptom ratings and
functional ratings, imply self-reported ADHD symptom
scales to be reliable. An increased use of self-reported
symptom scales, preferably combined with, for instance,
the more easily observer-rated CGI, might facilitate
monitoring of pharmacological treatment in regular clin-
ical practice and might be cost-saving as well. Further, as
the results on the Conners’ CPT (see Fig. 3) almost nor-
malized as compared to the norm by treatment with
OROS-methylphenidate, it might be that more ecologi-
cally valid outcome measures need to be used in future
trials when evaluating ‘add-on’ treatments to pharmaco-
logical treatment in a multimodal approach, to reduce the
possibility of ceiling effects.
In conclusion, OROS-methylphenidate was an effective
and overall safe treatment for adult male prison inmates
with ADHD and coexisting disorders, both in the short
term and in the long term. As this was the first study
evaluating stimulant treatment for prison inmates with
ADHD within a prison environment, our results need to be
confirmed.
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